Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing. Huagai Capital led the round.
Source: Press Release
Immvira nets $58m Series B
Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: